Getein Biotech has released its earnings forecast, projecting attributable net profit for the first half of 2026 at 170 million to 200 million yuan, a year-on-year increase of 56.24% to 83.81%. Deducted non-recurring net profit is expected to be 110 million to 130 million yuan, up 17.99% to 39.44%. The company said the profit growth is mainly due to enhanced competitiveness in overseas markets, with significant sales increases in core products such as point-of-care testing and chemiluminescence, driving higher operating revenue. In addition, the company completed the transfer of its 56.9766% stake in subsidiary Wuhan Jingchuan Diagnostic Technology, which contributed approximately 49.04 million yuan to net profit.
Getein Biotech IncEarnings forecast shows 56-84% net profit growth, driven by overseas sales and a subsidiary stake transfer.
Mentioned only as the subsidiary whose stake transfer contributed to Getein's profit; no independent impact.